PHRM 550/INSC 576 Adv. Topics in Neuropsychopharmacology

Aka:  Pharm 550, INSC 576, INSC 600-006 and 600-007, and Psyc 750

Course Director:           Irwin Lucki, Ph.D.

                                    Departments of Psychiatry and Pharmacology

                                    2204 Translational Research Laboratory

                                    573-3305; 573-2149 (FAX); lucki@pharm.med.upenn.edu

Meeting:  Tues & Thursday, 1:00 – 2:15, First floor Conference Room (124), Translational Research Laboratory (125 South 31st Street)

Neuropsychopharmacology Part I.  Stress Neurobiology and  Substance Abuse

Section Director:  Rita J. Valentino, Ph.D.

9/11 1        Stress, corticotropin-releasing factor and emotional arousal       Rita Valentino

9/13 2        Impact of Steroid Hormones on Brain Neurons                               Sheryl Beck     

9/18 3        Genetic Models of Stress Vulnerability                                                 Tracy Bale

9/20 4        Neuroendcrinology of the stress response                               Seema Bhatnagar

9/25 5        Clinical Aspects of Stress Disorders                                                       Elna Yadin

Section II:  Substance Abuse Disorders

Section Director:  Laura Peoples, Ph.D.

9/27 6        Clinical Overview of Substance Use Disorders                                            Charles Dackis

                  (Definitions, approaches, epidemiology)

10/2 7        Neuroimaging Studies of Human Substance Abusers                                   Anna Rose Childress

10/4 8        Behavioral Models of Addiction                                                           Laura Peoples

10/9 9        Neural Mechanisms of Reward in Addiction                                    Laura Peoples

10/11 10    Stress and Substance Abuse                                                           Julie Blendy

10/16 11    Addiction to Nicotine                                                                            Caryn Lerman

10/18 12    Genetics Mechanisms of Substance Abuse                                  Wade Berrettini

Neuropsychopharmacology Part II.  Affective Disorders and Schizophrenia

Section III:  Depression and Anxiety

Section Directors: Irwin Lucki, Ph.D. and Wade Berrettini, M.D., Ph.D.

10/23 13    Clinical Overview of Affective Disorders                                         Wade Berrettini

10/25 14    Genetic Mechanisms Underlying Affective Disorders                   Wade Berrettini

10/30 15    Involvement of the GSK System in Lithium and Bipolar Disease       Peter Klein

11/1 16      Clinical Overview of Anxiety Disorders                                                     Irwin Lucki

11/6           Neuroscience Meeting – no class

11/8 17      Pharmacology of Antidepressant and Anxiolytic Drugs                         Irwin Lucki

11/13 18    Animal Models of Depression and Anxiety Disorders                           Irwin Lucki

Section IV:  Schizophrenia

Section Director:  Steven Arnold, M.D.

11/15 19    Clinical Overview of Schizophrenia                                                 Bruce Turetsky

11/20 20    Genetics of Schizophrenia                                                               Wade Berretini

11/27 21    Imaging and Neuropsychology of Schizophrenia                          Daniel Ragland

11/29 22    Animal Models for Behavior and Neurobiology                                 Steven Siegel

12/4 23      Cellular and Molecular Neuropathology of Schizophrenia             Steven Arnold

12/6 24      Clinical Pharmacology and Treatment of Schizophrenia     Steven Siegel